(Total Views: 166)
Posted On: 09/30/2024 4:57:52 PM
Post# of 113
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO Joins Expert Panel at Long COVID, RECOVER TLC Workshop
Tonix Pharmaceuticals (NASDAQ: TNXP) CEO Seth Lederman, MD, participated at a recent event hosted by the Foundation for the National Institutes of Health (“FNIH”) and the National Institute of Allergy and Infectious Diseases (“NIAID”). According to an announcement from the fully integrated biopharmaceutical company, Lederman was a panel member at the “RECOVER Treating Long COVID – Navigating the Pathway Forward” workshop, which was held last week in Bethesda, Maryland. During the panel, experts discussed clinical trial endpoints that could provide meaningful data to support regulatory approval of potential Long COVID therapeutics.
“We were honored to be invited to participate in the Long COVID workshop to discuss the progress of the RECOVER study and to plan the path forward for developing drugs to treat Long COVID,” said Tonix Pharmaceuticals CEO Seth Lederman, MD, in the press release. “We welcomed the opportunity to share lessons from our development of TNX-102 SL for fibromyalgia-type Long COVID and also for fibromyalgia, for which we expect to submit the New Drug Application (‘NDA’) to the U.S. Food and Drug Administration (FDA) in October.”
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Tonix Pharmaceuticals (NASDAQ: TNXP) CEO Seth Lederman, MD, participated at a recent event hosted by the Foundation for the National Institutes of Health (“FNIH”) and the National Institute of Allergy and Infectious Diseases (“NIAID”). According to an announcement from the fully integrated biopharmaceutical company, Lederman was a panel member at the “RECOVER Treating Long COVID – Navigating the Pathway Forward” workshop, which was held last week in Bethesda, Maryland. During the panel, experts discussed clinical trial endpoints that could provide meaningful data to support regulatory approval of potential Long COVID therapeutics.
“We were honored to be invited to participate in the Long COVID workshop to discuss the progress of the RECOVER study and to plan the path forward for developing drugs to treat Long COVID,” said Tonix Pharmaceuticals CEO Seth Lederman, MD, in the press release. “We welcomed the opportunity to share lessons from our development of TNX-102 SL for fibromyalgia-type Long COVID and also for fibromyalgia, for which we expect to submit the New Drug Application (‘NDA’) to the U.S. Food and Drug Administration (FDA) in October.”
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
